Inventor · disambiguated record
Stephen M. G. Gottschalk
Also filed as: GOTTSCHALK STEPHEN · GOTTSCHALK STEPHEN M G
7 granted patents·32 pending applications·27 citations·filing 2011–2024
77Inventor score
Files withST JUDE CHILDRENS RES HOSPITAL INC16BAYLOR COLLEGE MEDICINE15UNIV CHICAGO3BRENNER MALCOLM1GOTTSCHALK STEPHEN M G1
Top patents by PatentIndex Score
39 records- 0186US9493740B2Immunotherapy of cancer using genetically engineered GD2-specific T cellsBRENNER MALCOLM·Filed 2011·Granted Nov 15, 2016·25 cites·5 claims
- 0280US11219646B2Chimeric antigen receptor therapy with reduced cytotoxicity for viral diseaseBAYLOR COLLEGE MEDICINE·Filed 2017·Granted Jan 11, 2022·2 cites·35 claims
- 0373US2024025961A1CAR T-CELLS RECOGNIZING CANCER-SPECIFIC IL 13Ra2UNIV CHICAGO·Filed 2023·Application pending·0 cites
- 0469US2025002558A1Constitutively active cytokine receptors for cell therapyBAYLOR COLLEGE MEDICINE·Filed 2024·Application pending·0 cites
- 0568US11673935B2Car T-cells recognizing cancer-specific IL 13Ra2UNIV CHICAGO·Filed 2019·Granted Jun 13, 2023·0 cites·5 claims
- 0666US2023331819A1Antibody based gene therapy with tissue-directed expressionBAYLOR COLLEGE MEDICINE·Filed 2023·Application pending·0 cites
- 0762US2025257388A2Pre-effector car-t cell gene signaturesST JUDE CHILDRENS RES HOSPITAL INC·Filed 2022·Application pending·0 cites
- 0859US2025064933A1Chimeric antigen receptors comprising a pdz binding motifST JUDE CHILDRENS RES HOSPITAL INC·Filed 2022·Application pending·0 cites
- 0959US2025283110A1Methods and compositions for transduction of nk cellsST JUDE CHILDRENS RES HOSPITAL INC·Filed 2022·Application pending·0 cites
- 1058US2025346649A1Zip cytokine receptorsST JUDE CHILDRENS RES HOSPITAL INC·Filed 2022·Application pending·0 cites
- 1155US12102652B2Constitutively active cytokine receptors for cell therapyBAYLOR COLLEGE MEDICINE·Filed 2017·Granted Oct 1, 2024·0 cites·21 claims
- 1254US11566063B2Antibody based gene therapy with tissue-directed expressionBAYLOR COLLEGE MEDICINE·Filed 2017·Granted Jan 31, 2023·0 cites·5 claims
- 1353US2025195658A1Bispecific chimeric antigen receptors targeting grp78 and cd123 or grp78 and b7h3ST JUDE CHILDRENS RES HOSPITAL INC·Filed 2023·Application pending·0 cites
- 1453US2023174653A1B7-h3 chimeric antigen receptorsST JUDE CHILDRENS RES HOSPITAL INC·Filed 2021·Application pending·0 cites
- 1552US2018170992A1CAR T CELLS RECOGNIZING CANCER-SPECIFIC IL 13Ra2UNIV CHICAGO·Filed 2016·Application pending·0 cites
- 1651US12448426B2Chimeric antigen receptors with MYD88 and CD40 costimulatory domainsST JUDE CHILDRENS RES HOSPITAL INC·Filed 2019·Granted Oct 21, 2025·0 cites·10 claims
- 1751US2016000842A1Oncolytic virusBAYLOR COLLEGE MEDICINE·Filed 2014·Application pending·0 cites
- 1850US2023030680A1Chimeric gmcsf-il18 receptorST JUDE CHILDRENS RES HOSPITAL INC·Filed 2021·Application pending·0 cites
- 1949US2023016709A1Use of protease serine 21 (prss21) antigen testing in the diagnosis and treatment of acute myeloid leukemiaST JUDE CHILDRENS RES HOSPITAL·Filed 2020·Application pending·0 cites
- 2048US2024216427A1Chimeric antigen receptors targeting splice variants of the extracellular matrix proteins tenascin c (tnc) and procollagen 11a1 (col11a1)ST JUDE CHILDRENS RES HOSPITAL INC·Filed 2021·Application pending·0 cites
- 2148US2016015749A1Engager cells for immunotherapyBAYLOR COLLEGE MEDICINE·Filed 2014·Application pending·0 cites
- 2247US2019117692A1Engager cells for immunotherapyBAYLOR COLLEGE MEDICINE·Filed 2018·Application pending·0 cites
- 2347US2024366759A1Method for preserving developmental potential of immune cells used for adoptive cellular therapiesST JUDE CHILDRENS RES HOSPITAL INC·Filed 2022·Application pending·0 cites
- 2446US2018104337A1Chimeric cd27 receptors for redirecting t cells to cd70-positive malignanciesBAYLOR COLLEGE MEDICINE·Filed 2017·Application pending·0 cites
- 2546US2023312671A1Grp78 targeted adoptive cell therapyST JUDE CHILDRENS RES HOSPITAL INC·Filed 2021·Application pending·0 cites
- 2645US2016024175A1Chemotherapy-resistant immune cellsBAYLOR COLLEGE MEDICINE·Filed 2014·Application pending·0 cites
- 2745US2023340067A1Methods of generating an activation inducible expression system in immune cellsST JUDE CHILDRENS RES HOSPITAL INC·Filed 2021·Application pending·0 cites
- 2844US2017027988A1Immunotherapy of cancer using genetically engineered gd2-specific t cellsBAYLOR COLLEGE MEDICINE·Filed 2016·Application pending·0 cites
- 2944US2014086888A1Ebv-specific cytotoxic t-lymphocytes for the treatment of locoregional nasopharyngeal carcinoma (npc)HESLOP HELEN E·Filed 2011·Application pending·0 cites
- 3044US2023340040A1Chimeric myd88 receptorsST JUDE CHILDRENS RES HOSPITAL INC·Filed 2021·Application pending·0 cites
- 3144US2013323214A1Chimeric cd27 receptors for redirecting t cells to cd70-positive malignanciesGOTTSCHALK STEPHEN M G·Filed 2011·Application pending·0 cites
- 3243US11649284B2Cancer gene therapy targeting CD47BAYLOR COLLEGE MEDICINE·Filed 2017·Granted May 16, 2023·0 cites·15 claims
- 3342US2016015750A1Vascular-targeted t-cell therapyBAYLOR COLLEGE MEDICINE·Filed 2014·Application pending·0 cites
- 3442US2022226379A1Dnmt3a knock-out stat5 activated genetically engineered t-cellsST JUDE CHILDRENS RES HOSPITAL INC·Filed 2020·Application pending·0 cites
- 3542US2022326216A1T cell gene expression analysis for use in t cell therapiesST JUDE CHILDRENS RES HOSPITAL INC·Filed 2020·Application pending·0 cites
- 3641US2022195007A1Chimeric antigen receptors with cd20 safety switchST JUDE CHILDRENS RES HOSPITAL INC·Filed 2020·Application pending·0 cites
- 3735US2019307799A1Engineered lymphocytesUNIV MICHIGAN REGENTS·Filed 2017·Application pending·0 cites
- 3833US2018079824A1HER2/ErbB2 Chimeric Antigen ReceptorBAYLOR COLLEGE MEDICINE·Filed 2016·Application pending·0 cites
- 3932US2017281683A1Glypican-3 specific chimeric antigen receptors for adoptive immunotherapyBAYLOR COLLEGE MEDICINE·Filed 2015·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →